HBIO · Stage, GEX levels and seasonality
Harvard Bioscience Inc (HBIO)
Last close $9.39 (+1.9%) on 2026-11-13
No card. The trial ends after 7 days unless you choose a paid plan. There is no automatic charge.
Open the chartWeinstein stage
Stage 2B — Advancing (extended) · 12 weeks in this stage · 30-week average $7.06
Stage 2 (advancing): price holds above a rising 30-week average. The stage Weinstein buys.
What would change it: Stage 3 begins if the 30-week SMA (7.06) stops rising while price works around it, or after 3 straight weekly closes below it.
GEX levels
Call wall, put wall and gamma flip for HBIO are on Signa plans. What GEX levels tell you.
Seasonality
| Month | Average return | Months up | Years |
|---|---|---|---|
| January | -19.56% | 0% | 3 |
| February | -12.1% | 25% | 4 |
| March | -2.34% | 25% | 4 |
| April | +9.2% | 50% | 4 |
| May | +2.31% | 50% | 4 |
| June | -3.49% | 25% | 4 |
| July | -2.62% | 25% | 4 |
| August | +8.27% | 50% | 4 |
| September | -6.29% | 25% | 4 |
| October | +5.57% | 50% | 4 |
| November (this month) | +13.38% | 67% | 3 |
| December | +1.46% | 33% | 3 |
Based on up to 4 years of weekly closes. Past seasonality does not predict future returns.
On Signa plans
The Signa score and Action Card for HBIO, live options flow, dark pool prints, today's GEX levels with vanna and charm, and what 40+ AI agents say about it.
No card. The trial ends after 7 days unless you choose a paid plan. There is no automatic charge.
Questions about HBIO
What Weinstein stage is HBIO in?
HBIO is in Stage 2B — Advancing (extended), for 12 weeks, based on completed weekly bars and its 30-week moving average (7.06).
How has HBIO done in November?
Over the last 3 years, HBIO averaged +13.38% in November and rose in 67% of them. Past seasonality does not predict future returns.
Educational content only, not financial advice. Trading involves substantial risk.